Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review
Ming Poi(Caris Life Sciences (United States)), Robert Wesolowski(The Ohio State University Wexner Medical Center), Charles L. Shapiro(Tisch Hospital), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Bhuvaneswari Ramaswamy(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Michael Berger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin M. Olson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 36
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
|JAMA|2017|357
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296
Triple-negative breast cancer: promising prognostic biomarkers currently in development
|Expert Review of Anticancer Therapy|2020|236